Company news

Share this article:
Valeant Pharmaceuticals has announced a definitive agreement to acquire Dow Pharmaceutical Sciences, a privately held dermatology company, for $285 million. Dow Pharmaceutical Sciences' current annualized revenues are approximately $45 million, of which roughly $20 million represents royalty payments from licensed products.
 
Wyeth will cut 276 workers in Puerto Rico as a result of decreasing demand for locally manufactured products. The layoffs will be completed by February 2009, with 2,700 workers remaining across three plants in the US Caribbean territory, the AP reported.
 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.